Trade Ocugen, Inc. - OCGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0184 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.1258 |
| Open | 1.1358 |
| 1-Year Change | 177.02% |
| Day's Range | 1.1358 - 1.2358 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 9, 2024 | 1.2358 | 0.1000 | 8.80% | 1.1358 | 1.2358 | 1.1358 |
| Sep 6, 2024 | 1.1258 | -0.0500 | -4.25% | 1.1758 | 1.1858 | 1.1158 |
| Sep 5, 2024 | 1.1758 | 0.0300 | 2.62% | 1.1458 | 1.1758 | 1.1458 |
| Sep 4, 2024 | 1.1558 | -0.0300 | -2.53% | 1.1858 | 1.1858 | 1.1558 |
| Sep 3, 2024 | 1.2058 | -0.0800 | -6.22% | 1.2858 | 1.2858 | 1.1758 |
| Aug 30, 2024 | 1.2958 | 0.0400 | 3.19% | 1.2558 | 1.2958 | 1.2458 |
| Aug 29, 2024 | 1.2658 | -0.0500 | -3.80% | 1.3158 | 1.3158 | 1.2658 |
| Aug 28, 2024 | 1.2758 | -0.0300 | -2.30% | 1.3058 | 1.3158 | 1.2358 |
| Aug 27, 2024 | 1.3258 | -0.0100 | -0.75% | 1.3358 | 1.3758 | 1.3058 |
| Aug 26, 2024 | 1.3558 | 0.0700 | 5.44% | 1.2858 | 1.3858 | 1.2858 |
| Aug 23, 2024 | 1.2858 | 0.0600 | 4.89% | 1.2258 | 1.2858 | 1.2258 |
| Aug 22, 2024 | 1.2158 | -0.0600 | -4.70% | 1.2758 | 1.2858 | 1.2158 |
| Aug 21, 2024 | 1.2758 | 0.0700 | 5.81% | 1.2058 | 1.2858 | 1.2058 |
| Aug 20, 2024 | 1.2058 | -0.0500 | -3.98% | 1.2558 | 1.2658 | 1.1958 |
| Aug 19, 2024 | 1.2758 | 0.0300 | 2.41% | 1.2458 | 1.2958 | 1.2358 |
| Aug 16, 2024 | 1.2358 | -0.0500 | -3.89% | 1.2858 | 1.2958 | 1.2158 |
| Aug 15, 2024 | 1.2958 | 0.0100 | 0.78% | 1.2858 | 1.3058 | 1.2758 |
| Aug 14, 2024 | 1.2758 | -0.0400 | -3.04% | 1.3158 | 1.3258 | 1.2658 |
| Aug 13, 2024 | 1.3058 | 0.0000 | 0.00% | 1.3058 | 1.3358 | 1.2658 |
| Aug 12, 2024 | 1.3058 | 0.0700 | 5.66% | 1.2358 | 1.3058 | 1.2358 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Ocugen, Inc. Company profile
Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine.
Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.
Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases.
For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.
The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).
The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD).
Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.
Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.
Ocugen is headquartered in Malvern, Pennsylvania.
| Industry: | Biotechnology & Medical Research (NEC) |
11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US
News
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024
Global selloff continues on US economy fears
Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.
14:40, 5 August 2024
FOMC PREVIEW
Markets believe the Federal reserve will continue to leave their monetary policy unchanged at the meeting next week.
14:09, 1 August 2024
How to manage risk when trading
Learn what risk management is and find out how understanding about it could help you identify potential risks in your investment portfolio. Find out more.
06:57, 22 July 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com